<DOC>
	<DOCNO>NCT00711009</DOCNO>
	<brief_summary>The purpose study compare safety , tolerability , antiviral activity lopinavir/ritonavir tablet administer combination reverse transcriptase inhibitor lopinavir/ritonavir tablet administer combination human immunodeficiency virus type 1 ( HIV-1 ) integrase inhibitor antiretroviral naive HIV-1 infected subject .</brief_summary>
	<brief_title>Study Comparing Lopinavir/Ritonavir ( LPV/r ) + Emtricitabine/Tenofovir Disoproxil Fumarate ( FTC/TDF ) With Nucleoside Sparing Regimen Consisting Lopinavir/Ritonavir + Raltegravir ( RAL )</brief_title>
	<detailed_description />
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<criteria>Participants must provide write , voluntary inform consent participate study . Participants must naive antiretroviral treatment HIV RNA great equal 1,000 copies/mL screening , investigator 's opinion , require antiretroviral therapy . Participant 's vital sign , physical examination , laboratory result must exhibit evidence acute illness . Participant treat active acquire immune deficiency syndrome ( AIDS ) define opportunistic infection within 45 day initiate study drug . Participants stable maintenance therapy opportunistic infection may enrol consultation Sponsor . Participant require agrees take drug contraindicate significant pharmacokinetic interaction study drug course study . Participant agrees take medication study , include overthecounter medicine , vitamin , mineral , herbal preparation , alcohol , recreational drug without knowledge permission principal investigator . Female participant must either postmenopausal least one year , surgically sterile , must use nonhormonal method birth control acceptable participant investigator . All female participant must urine pregnancy test perform screening visit Day minus 1/baseline , result test must negative . Female participant may breastfeed . Participants receive prior treatment HIV1 integrase inhibitor . Participants must history allergic reaction significant sensitivity study drug . Participants may ongoing history substance abuse psychiatric illness could preclude protocol adherence . Participant resistance lopinavir/ritonavir , tenofovir , emtricitabine base HIV1 drug resistance genotypic test result screen visit . Participant may significant medical history concomitant illness disease would adversely affect his/her participate study . Participants may receive investigational drug investigational vaccine within 30 day prior study drug administration . Participants may follow abnormal screen result : Hemoglobin &lt; = 8.0 grams/deciliter , absolute neutrophil count &lt; = 750 cells/microliter , Platelet count &lt; = 50,000 per milliliter , alanine aminotransferase ( ALT ) ( serum glutamicpyruvic transaminase [ SGPT ] ) aspartate aminotransferase ( AST ) ( serum glutamic oxaloacetic transaminase [ SGOT ] ) &gt; = 3.0 x upper limit normal ( ULN ) , calculate creatinine clearance &lt; 50 milliliter/minute , hepatitis B surface antigen ( HBsAg ) positive . The investigator considers participant unsuitable candidate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Human Immunodeficiency Virus infection</keyword>
</DOC>